TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05729178

Intervention type: OTHER
Intervention: observational study
Description: analysis of biomarkers of interest (DNA-RNA and proteins) in MNC purified from the subjects' blood

Intervention type: OTHER
Intervention: observational study
Description: analysis of biomarkers of interest (DNA-RNA and proteins) in MNC purified from the subjects' blood
Study: NCT04460274

Intervention type: OTHER
Intervention: Model Building
Description: Model building

Intervention type: OTHER
Intervention: Model validation
Description: Model validation
Study: NCT02641600

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Elastic stockings
Description: Use of elastic stockings to alleviate patient symptoms

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo stockings
Description: Placebo stocking with pressure applied to the legs
Study: NCT01347762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nabilone
Description: nabilone titrated to 1 mg by mouth twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one placebo capsule by mouth twice daily
Study: NCT04451174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 40 mg days 1 to 4. Then, prednisone 20 mg days 5 to 8.
Study: NCT00827866

Intervention type: OTHER
Group type: OTHER
Intervention: Counselor-Initiated Tobacco Quit Line
Description: The proposed active intervention will be a the Counselor-Initiated QL which includes provision of 8 weeks of nicotine replacement therapy (NRT) and six scheduled telephone sessions of a behavioral intervention.

Intervention type: OTHER
Group type: OTHER
Intervention: Self-Paced Tobacco Quit Line
Description: The comparison condition will be the Self-Paced QL with provision of 2 weeks of NRT and encouraged obtainment of additional NRT. If participants in the Self-Paced condition make all six calls, they will receive the same behavioral intervention as in the Counselor-Initiated condition.
Study: NCT02216305

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemorrhoidectomy
Description: Open hemorrhoidectomy may include one to three anal cushions and made according to the Milligan-Morgan technique, with resection of the anal cushion and the external hemorrhoidal epidermal component using electrocautery and ligation of the hemorrhoidal base with absorbable suture

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HAL-RAR
Description: Hemorrhoidal artery ligation and rectoanal repair will be performed with the AMI minimally invasive surgery device HAL/RAR, and consist in the ligation of the terminal branches of the superior rectal artery with 2-0 absorbable polyglycolic acid suture after identifying the blood flow approximately 3 cm above the dentate line by using Doppler guidance. Subsequently, a running suture was added from the suture point to 5 mm above the dentate line to lift the prolapsing hemorrhoid. Other procedures will not be associated.
Study: NCT01115660

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stroke education
Description: call by medication coach 2 weeks after hospital discharge
Study: NCT00598143

Intervention type: BEHAVIORAL
Intervention: Vignette, questionnaires and Saliva Samples
Description: The short vignette discusses the health implications of potential molecular markers of cancer risk assessment. The questionnaire asks several multiple-choice questions to assess the participant's interest in and understanding of molecular risk assessment. Patients are instructed to swish with 10cc of Scope mouthwash and to expectorate into a sterile 50cc conical tube.

Intervention type: BEHAVIORAL
Intervention: Urine Collection, Smoking cessation treatment
Description: Single void urine specimens (approximately 50 ml) will be collected in pre-labeled specimen containers on a 3-monthly (±1 month) basis for 12 months. Standard evidence-based therapy for smoking cessation, including behavioral therapy and pharmacological therapy, is provided.
Study: NCT03248154

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Procellera
Description: burn dressing
Study: NCT03371381

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JNJ-64041757
Description: Participants will receive intravenous (IV) infusions of JNJ-64041757 over approximately 60 minutes during each treatment cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Participants will receive IV infusions of nivolumab over approximately 60 minutes during each treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Participants will receive IV infusions of nivolumab over approximately 60 minutes during each treatment cycle.
Study: NCT05525884

Intervention type: OTHER
Intervention: non-invasive method, Fibroscan
Description: Liver Ultrasound and transient elastography (FibroScan®)

Intervention type: OTHER
Intervention: non-invasive method, Fibroscan
Description: Liver Ultrasound and transient elastography (FibroScan®)

Intervention type: OTHER
Intervention: non-invasive method, Fibroscan
Description: Liver Ultrasound and transient elastography (FibroScan®)
Study: NCT03018054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6007
Description: once daily administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6007
Description: once daily administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily administration
Study: NCT02631512

Intervention type: DEVICE
Group type: OTHER
Intervention: Woulgan Gel
Description: Primary dressing gel to be applied to the wound bed, and to be covered with a secondary bandage.

Intervention type: DEVICE
Group type: OTHER
Intervention: Intrasite Hydrogel
Description: Primary dressing hydrogel to be applied to the wound bed, and to be covered with a secondary bandage
Study: NCT00680784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HKT-500 Ketoprofen Topical Patch
Description: HKT-500 Ketoprofen Topical Patch
Study: NCT04246684

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin, 85 mg/m2
Description: 85 mg/m2,2h-civ, day 22, 36, 50, 64, 78, 92, 106, 120, and 134 of therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5FU; 2400 mg/m2
Description: 2400 mg/m2, 46h-civ, day 22, 36, 50, 64, 78, 92, 106, 120, 134 of therapy for Control arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5FU, 250 mg/m2
Description: 250 mg/m2 per day, civ, on day 1-14, day 22-35 of radiotherapy;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5FU, 2400 mg/m2
Description: 2400 mg/m2,46h-civ, d64, d78, d92, d106, d120, d134 of therapy
Study: NCT00680784

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: Placebo Patch
Study: NCT01210664

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells
Description: The researchers will multiply/expand the Tregs in the laboratory using anti-CD3/anti-CD28 coated beads plus IL-2. Then, the Tregs will be infused back into the patient in a single infusion. The first cohort will receive 0.05 x10\^8 cells. The second cohort will receive 0.4 x10\^8 cells. The third cohort will receive 3.2 x10\^8 cells. The fourth cohort will receive 26 x10\^8 cells.
Study: NCT00552240

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tenofovir DF 300 mg QD
Description: 300 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tenofovir DF 300 mg QD
Description: 300 mg QD
Study: NCT04246684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin 50 mg/m2
Description: 50 mg/m2, 2h-civ, d1, d8, d21, d29 of radiotherapy and

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folinic Acid, 400 mg/m2
Description: 2h-civ day 22, 36, 50, 64, 78, 92, 106, 120, and 134 of therapyfor Control arm; 400 mg/m2, 2h-civ d 64, d78, d92, d106, d120, d134 of therapy for experimental arm
Study: NCT00552240

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: emtricitabine 200 mg QD
Description: 200 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: emtricitabine 200 mg QD
Description: 200 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine 200 mg BID
Description: 200 mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir 300 mg
Description: 300 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir 100 mg
Description: 100 mg QD
Study: NCT00580645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline
Description: 2mg/day or 1mg/day with 1-week medication lead-in period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT02679573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delafloxacin
Description: Antibacterial agent, 300 mg IV, Q12H for at least 6 doses with potential to switch to 450 mg oral tablet, Q12H for up to 20 doses total
Study: NCT04246684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid, 400 mg/m2
Description: 2h-civ day 22, 36, 50, 64, 78, 92, 106, 120, and 134 of therapyfor Control arm; 400 mg/m2, 2h-civ d 64, d78, d92, d106, d120, d134 of therapy for experimental arm

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy control, 5x5 Gy: 25 Gy
Description: Control arm: 5x5 Gy (total: 25 Gy) 5 fractions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine, 1000 mg/m2
Description: 1000 mg/m2 (twice daily) day1-14 every three weeks instead of 5FU optional

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine, 1000 mg/m2
Description: 1000 mg/m2 (twice daily) day1-14 every three weeks instead of 5FU optional

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin 85 mg/m2
Description: 85 mg/m2, 2h-civ, d64, d78, d92, d106, d120, d134 of therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy experimental, 30 x 1,8 Gy: 54 Gy
Description: 30 x 1.8 Gy (total: 54 Gy), 5 fractions per week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine, 825 mg/m2
Description: 825 mg/m2 bid, per os, on day 1-14, 22-35 of RT instead of 5FU optional

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin, 130 mg/m2
Description: day1every three weeks (optional)
Study: NCT02679573

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Antibacterial Agent, 400 mg IV, Q24H for at least 3 doses with potential to switch to 400 mg oral over-encapsulated tablet, Q24H for up to 10 doses total

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: Antibacterial Agent, at local investigator discretion, subjects in the moxifloxacin arm with confirmed MRSA can switch to linezolid 600 mg IV Q12H for all remaining doses
Study: NCT01096485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel Emergency Pill (BAY86-5028/Opxion)
Description: Single dose of 1.5 mg coated tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel (Postday)
Description: Single dose of two 0.75 mg tablets
Study: NCT01351831

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation with strength training
Description: The rehabilitation programme lasts 1 hour per session, and is performed twice per week for 7 weeks. The rehabilitation program consists of balance-, mobility- and functional training exercises etc. In addition, the participants perform unilateral (operated leg) knee-extensions and leg presses in 2 sets for each strength training exercise, using relative loads of 12 RM (week 1), 10 RM (weeks 2-5), and 8 RM (week 6-7). All sets are performed to failure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation without strength training
Description: The rehabilitation programme lasts 1 hour per session, and is performed twice per week for 7 weeks. The rehabilitation program consists of the same balance-, mobility- and functional training exercises etc. as used in the other experimental arm.
Study: NCT02545023

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Complete an in-person one-on-one interview

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete the demographics questionnaire, SCNS-34, SF-36, and Lifestyle Needs Survey
Study: NCT00149760

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Augmented Standard Medical Care
Description: Participants' physicians will receive a letter making specific treatment recommendations for primary care treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Affective Behavior Therapy
Description: Individually-administered cognitive-behavioral therapy with an emotional focus in addition to augmented standard medical care
Study: NCT01947985

Intervention type: DRUG
Intervention: Rivaroxoban (Xarelto, Bay59-7939)
Description: The treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE), and prevention of recurrent DVT and PE in adult patients (15 mg rivaroxaban twice daily \[bid\] for 3 weeks, then 15 mg or 20 mg once daily \[od\], tablets).~The prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (stroke prevention in atrial fibrillation \[SPAF\]) with one or more risk factors (20 mg rivaroxaban \[od\], tablets).~The prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery (recommended dose: 10 mg rivaroxaban \[od\] tablets for 35 days following hip replacement surgery and 14 days following knee replacement surgery).~Co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (recommended dose 2.5 mg rivaroxaban tablets \[bid\]).

Intervention type: DRUG
Intervention: Standard of care
Description: For DVT/PE treatment and SPAF, standard of care is treatment with the most widely used vitamin K antagonist, phenprocoumon, and for the secondary prevention of ACS, standard of care is antiplatelet drug(s) such as low-dose acetylsalicylic acid, clopidogrel, dipyridamole, prasugrel, ticlopidine and ticagrelor.
Study: NCT00297596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab will be administered as an 8 mg/kg loading dose by intravenous (IV) infusion over 90 minutes on day 1 of cycle 1. Subsequent doses will be administered as a 6 mg/kg IV dose over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered at a dose of 130 mg/ m2 over 120 minutes on day 1 of each cycle, following standard antiemetic premedications. 21 day cycles.~For the first cycle, trastuzumab will be administered before oxaliplatin; however for subsequent cycles, oxaliplatin will be infused prior to trastuzumab
Study: NCT04304521

Intervention type: PROCEDURE
Intervention: Lung recruitment maneuver
Description: Lung recruitment maneuver is used to reopen or prevent collapsed lung under mechanical ventilation so as to decrease respiratory complications. LRM induces a transient increase in intra-thoracic pressure and decreases in venous return, leading to a decrease in left ventricular end-diastolic area and stroke volume.
Study: NCT02717572

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F 18

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computerized Tomography

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Study: NCT00669526

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BCBT
Description: Brief Cognitive Behavioral Therapy. This BCBT protocol consists of up to 8 CBT sessions to be conducted over a maximum of 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMHC referral
Description: Referral to local Speciality Mental Health Care. Families were referred to local mental health care providers, and could freely choose any treatment or combination of treatments offered (e.g., anti-depressant medication, individual psychotherapy, family psychotherapy, etc.).
Study: NCT01667211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin-bound paclitaxel plus nedaplatin
Description: intravenous albumin-bound paclitaxel, 175-200 mg/m2, d 1, was given every 3 weeks, combined with intravenous nedaplatin, 80- 100 mg/m2, d 2. At least 2 cycles will be completed for each patient, for whom responds to study treatment, 4-6 cycles will be completed.
Study: NCT04395027

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: atrial septal defect closure
Description: The iatrogenic septal defect will be closed in the usual manner
Study: NCT02764294

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music Group
Description: Music group was listened to a music of their choise with a headset. The music intervention was started about 10-15 minutes before cystoscopy and continued during the whole procedure. Types of music were Turkish folk music, Turkish art music, Turkish arabesque music, Turkish pop music, foreign pop music, rock music, and classical music.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stress Ball Group
Description: Music group was given stress ball into both their palms about 10-15 minutes before cystoscopy. Participants were instructed to squeeze the balls twice after counting up to five and repeat it until the end of the procedure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DVD Group
Description: DVD group was started to be watched a DVD of their choise about 10-15 minutes before cystoscopy and continued during the whole procedure.
Study: NCT03465098

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strict low carbohydrate diet (< 3gr/day of carbohydrate) before a 18F-FDG PET/CT
Description: The patients will receive 2 PET/CT , first exam with standard diet preceded by 12h fasting and second exam preceded by 3 meals strict low diet and 12h fasting
Study: NCT01853137

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixed Lingual Mandibular Growth Modificator (FLMGM)
Description: Novel Class II functional appliance, a fixed version of double-plate appliance
Study: NCT02483585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: Administered once a month by subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered once a month by subcutaneous injection
Study: NCT03634020

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DynamX Sirolimus-eluting Coronary Bioadaptor System
Description: de novo native coronary artery lesions
Study: NCT01485055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab and Basiliximab
Description: Participants in this research study will receive combination therapy (2 drugs: Infliximab and Basiliximab)once a week for four weeks. Both drugs will be given through the participant's broviac, port or through a vein in the arm. It will take about 4-5 hours to complete the 2-drug combination therapy each week. Participants will be given pre-medications to help prevent reactions to the study drugs.~Infliximab will be given at a dose of 10mg per Kg per dose. Basiliximab will be given in 10mg doses to patients who weigh less than 35kg. Patients who weigh weigh more than 35kg will receive 20mg doses. Patients will receive both drugs weekly on days 1,8,15 and 22. Each drug will be given 4 times.
Study: NCT03987178

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dunk
Description: If randomized to Dunk, the subject is asked to submerge his or her head in the hot tub at least up to brow level.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposure to Hot Tub
Description: Subjects will be asked to sit in a hot tub for 15 minutes (with an individual timer).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exposure to Hot Tub
Description: Subjects will be asked to sit in a hot tub for 15 minutes (with an individual timer).
Study: NCT02042222

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyurea

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyurea
Study: NCT03830749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Eltrombopag Oral Tablet 25-75 mg daily for 12 weeks plus pulsed dexamethasone
Study: NCT01411215

Intervention type: DRUG
Intervention: Enbrel
Description: 25mg biweekly or 50mg per week, subcutaneous injection
Study: NCT00394082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-007
Description: 125 mg/m\^2 of ABI-007 administered by intravenously (IV) over 30 minutes on days 1, 8 and 15 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab administered once every 2 weeks (10 mg/kg) by IV infusion after ABI-007 has been given. The first dose is one Day 1, cycle 1.
Study: NCT00903630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: administered by mouth at the assigned dose daily for each 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: administered by mouth at the assigned dose daily for each 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: administered by mouth at the assigned dose daily for each 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal doxorubicin
Description: administered at a fixed dose of 40 mg/m\^2 intravenously (IV) on day 1 of each 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal doxorubicin
Description: administered at a fixed dose of 40 mg/m\^2 intravenously (IV) on day 1 of each 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal doxorubicin
Description: administered at a fixed dose of 40 mg/m\^2 intravenously (IV) on day 1 of each 28 day cycle
Study: NCT01553123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulipristal Acetate
Description: once daily, oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Iron
Description: once daily, dried ferrous sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron
Description: once daily, dried ferrous sulfate
Study: NCT03080831

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaCl 0.9% in Glucose 5% + 40mmol/L Potassium
Description: Study fluid used at maintenance rate of 27 mmol per kg of body weight per day from beginning of surgery until end of study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucion 5%
Description: Study fluid used at maintenance rate of 27 mmol per kg of body weight per day from beginning of surgery until end of study.
Study: NCT04525872

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Full parenteral nutrition light protection of the bag, tubing and lipids
Description: Each infant enrolled in this study will receive full PN light protection including the PN bag, lipids and tubing.